Compounds > topotecan
Page last updated: 2024-08-24

topotecan and sulfasalazine

topotecan has been researched along with sulfasalazine in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (37.50)29.6817
2010's5 (62.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Chen, X; Lin, X; Skolnik, S; Wang, J1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Báthori, G; Gedey, S; Glavinas, H; Janáky, T; Krajcsi, P; Méhn, D; Mészáros, P; Molnár, E; Nagy, T; Pál, A; Szente, L; von Richter, O1
Allen, JD; Arnold, JC; Holland, ML; Lau, DT1
Hashimoto, T; Konno, Y; Matsuda, Y; Nagai, M; Satsukawa, M; Taguchi, T; Yamashita, S1

Reviews

1 review(s) available for topotecan and sulfasalazine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

7 other study(ies) available for topotecan and sulfasalazine

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:2

    Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity

2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 321, Issue:3

    Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Baculoviridae; Benzimidazoles; Biological Transport, Active; Cell Line; Cell Membrane; Cholesterol; Estrone; Glycosylation; Humans; Kinetics; Methotrexate; Neoplasm Proteins; Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase; Pharmaceutical Preparations; Prazosin; Spodoptera; Sulfasalazine; Topotecan

2007
The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.
    British journal of pharmacology, 2007, Volume: 152, Issue:5

    Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cannabinoids; Cell Line; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Dronabinol; Flow Cytometry; Humans; Immunoblotting; Inhibitory Concentration 50; Mice; Mitoxantrone; Neoplasm Proteins; Plant Extracts; Receptor, Cannabinoid, CB1; Reverse Transcriptase Polymerase Chain Reaction; Sulfasalazine; Topotecan; TRPV Cation Channels

2007
In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats.
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:8

    Topics: Absorption; Adenosine; Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Catheterization; Dibenzocycloheptenes; Diketopiperazines; Heterocyclic Compounds, 4 or More Rings; Male; Portal Vein; Quinolines; Rats; Rats, Sprague-Dawley; Sulfasalazine; Terfenadine; Topotecan

2013